1: Arch Pediatr. 2003 Mar;10(3):244-5.
[Wireless-capsule video-endoscopy: preliminary results in children]
[Article in French]
Mallet E, Cron J, Stoller J.
Unite de gastro-enterologie, departement de pediatrie medicale, centre
hospitalier universitaire Charles-Nicolle, 1, rue Germont, 76031 cedex, Rouen,
France
PMID: 12829342 [PubMed - in process]
2: Rev Med Interne. 2003 Jul;24(7):476-7.
[Wernicke's encephalopathy after vertical banded gastroplasty for morbid
obesity]
[Article in French]
Houdent C, Verger N, Ahtoy P, Courtois H, Teniere P.
Departement de medecine interne, CHU de Rouen, 76031 cedex, Rouen, France
PMID: 12829223 [PubMed - in process]
3: J Med Chem. 2003 Jul 3;46(14):3072-3082.
Structure-Activity Relationships and Mechanism of Action of Antitumor
Benzo[b]pyrano[3,2-h]acridin-7-one Acronycine Analogues.
Thi Mai HD, Gaslonde T, Michel S, Tillequin F, Koch M, Bongui JB, Elomri A,
Seguin E, Pfeiffer B, Renard P, David-Cordonnier MH, Laine W, Bailly C,
Kraus-Berthier L, Leonce S, Hickman JA, Pierre A.
Laboratoire de Pharmacognosie de l'Universite Rene Descartes, U.M.R./C.N.R.S.
No. 8638, Faculte des Sciences Pharmaceutiques et Biologiques, 4 Avenue de
l'Observatoire, 75006 Paris, France, Laboratoire de Pharmacognosie de
l'Universite de Rouen-Haute Normandie, Faculte de Pharmacie, 22 Boulevard
Gambetta, 76183 Rouen Cedex, France, Les Laboratoires Servier, 1 rue Carle
Hebert, 92415 Courbevoie Cedex, France, INSERM U-524 et Laboratoire de
Pharmacologie Antiumorale du Centre Oscar Lambret, IRCL, 59045 Lille Cedex,
France, and Institut de Recherches Servier, Division Recherche Cancerologie, 125
Chemin de Ronde, 78290 Croissy sur Seine, France.
The cytotoxic and antitumor activities of
cis-1,2-diacyloxy-6-methoxy-3,3,14-trimethyl-1,2,3,14-tetrahydro-7H-benzo[b]pyra
no[3,2-h]acridin-7-one derivatives 3, 6-9 were strongly correlated with their
ability to give covalent adducts with purified, as well as genomic, DNA. Such
adducts involve reaction between the exocyclic N-2 amino group of guanines
exposed in the minor groove of double helical DNA and the leaving ester group at
the benzylic position 1 of the drug. A transesterification process of the ester
group from position 2 to position 1 in aqueous medium accounted for the intense
activity of the
cis-1-hydroxy-2-acyloxy-6-methoxy-3,3,14-trimethyl-1,2,3,14-tetrahydro-7H-benzo[
b]pyrano[3,2-h]acridin-7-one derivatives 10-13. Compounds without acyloxy or
hydroxy group at position 1, such as 15, 17, 18, and 22, were inert with respect
to DNA and almost devoid of significant cytotoxic activity. Condensation of
5-amino-2,2-dimethyl-2H-chromene (26) with 3-bromo-2-naphthoic acid (27),
followed by cyclization, gave access to 6-demethoxy analogues. Diacetate 32 and
cyclic carbonate 33, both belonging to the latter series, were less reactive
toward DNA and less cytotoxic than their 6-methoxy counterparts 3 and 34. DNA
alkylation appears thus to play an important role in the antitumor properties of
benzo[b]pyrano[3,2-h]acridin-7-one derivatives.
PMID: 12825945 [PubMed - as supplied by publisher]
4: Br J Haematol. 2003 Jul;122(1):163-4.
Have urinary levels of the angiogenic factors, basic fibroblast growth factor
and vascular endothelial growth factor, a prognostic value in childhood acute
lymphoblastic leukaemia?
Schneider P, Vasse M, Legrand E, Callat MP, Vannier JP.
Groupe de recherche sur le microenvironnement et le renouvellement cellulaire
integre, Hopital Charles- Nicolle, Hemato-oncologie pediatrique, and Hopital
Charles-Nicolle, Laboratoire hematologie, France. E-mail:
Pascale.Schneider@chu-rouen.fr
PMID: 12823361 [PubMed - in process]
5: Pacing Clin Electrophysiol. 2003 Jun;26(6):1410-2.
An atypical atrial flutter of focal origin: a study using a noncontact mapping
system.
Ouali S, Anselme F, Savoure A, Cribier A.
Department of Cardiology, Rouen University Hospital, Rouen, France.
We report a case of focal atrial tachycardia with appearance suggestive of
atypical atrial flutter in a 57-year-old man. Based on ECG criteria, tachycardia
was misclassified as atypical atrial flutter. The electrophysiological study
using a noncontact mapping system revealed a focal activity within the left
upper pulmonary vein ostium. This case highlights the limitations of standard
electrocardiographic and electrophysiological classifications of regular atrial
tachycardia. This report also shows the relevance of new mapping techniques in
the successful mapping and ablation of these arrhythmias, even those arising
within the left atrium.
PMID: 12822758 [PubMed - in process]
6: Gynecol Obstet Fertil. 2003 Apr;31(4):397.
[In Process Citation]
[Article in French]
Marpeau L.
Clinique gynecologique et obstetricale, hopital Charles-Nicolle, CHU de Rouen,
1, rue de Germont, 76031 cedex, Rouen, France
PMID: 12821074 [PubMed - in process]
7: Gynecol Obstet Fertil. 2003 Apr;31(4):388-92.
[In Process Citation]
[Article in French]
Belaisch-Allart J, Frydman R, Marpeau L.
PMID: 12821073 [PubMed - in process]
8: Graefes Arch Clin Exp Ophthalmol. 2003 Jun 18 [Epub ahead of print].
Long-term results of penetrating keratoplastyA 10-year-plus retrospective study.
Muraine M, Sanchez C, Watt L, Retout A, Brasseur G.
Department of Ophthalmology, Hospital Charles Nicolle, Boulevard Gambetta,
76031, Rouen cedex, France.
BACKGROUND. The aim of this study was to retrospectively analyse the outcome of
a series of grafted patients over a period of more than 10 years and to
determine their long-term survival probability. METHODS. The records of 89
patients who had 103 grafts performed in 97 eyes were analysed. Mean follow-up
was 12.8 years (range 10-17 years). Life table analysis (Kaplan-Meier) was used
to evaluate the graft survival of the total population and of different groups.
RESULTS. Eighteen out of 89 patients (20.2%) had died. At the last visit before
their death, 10 of the 21 grafts in those patients were still clear. Graft
survival rates after 1, 2, 5 and 10 years were 79%, 73%, 59% and 50%; the rate
at the end of follow-up was 47%. Survival rate at the end of the study was 94.7%
for keratoconus, 57.1% herpes keratitis, 33.3% for pseudophakic keratopathies,
28.5% for post-traumatic keratopathies and 11.1% for re-grafts. In the group of
patients grafted for aphakic or pseudophakic keratopathy, 40% died during the
study. In 45% of cases their grafts were clear at the time of death. Endothelial
decompensation and definitive graft rejection were the main causes of failure.
CONCLUSIONS. The outcome of keratoplasty is progressively getting worse with
time in pseudophakic or traumatic keratopathies whereas survival rates are still
stable from 10 to 17 years in grafts performed after keratoconus or herpetic
keratitis.
PMID: 12819978 [PubMed - as supplied by publisher]
9: Arch Pediatr. 2003 Apr;10(4):307-12.
[Association cefepime-amikacin in febrile neutropenic children with malignant
hemopathy or malignant tumour]
[Article in French]
Marie-Cardine A, Schneider P, Blot N, Tron P, Vannier JP.
Service d'immuno-hemato-oncologie pediatrique, centre hospitalier universitaire
Rouen, 1, rue de Germont, 76031 cedex, Rouen, France
Our aim was to evaluate retrospectively the efficacy of a therapeutic strategy
with a first line combination based on cefepime-amikacin in febrile neutropenic
children treated with chemotherapy.Patients and methods. - Sixty-five
neutropenic febrile episodes in 43 children treated by the association
cefepime-amikacin, were evaluated according to the clinical status, the depth
and duration of neutropenia, the underlying disease and the initial
treatment.Results. - Thirty-nine (60%) episodes were successfully treated by the
association cefepime-amikacin. Among the 26 persisting febrile episodes,
adjunction of vancomycin and amphotericin B was effective in 11 (76% of total
rate success) and 5 (84% of total rate success) cases respectively. The efficacy
of the first line antibiotherapy was not different as regards to the duration
and the depth of neutropenia. Otherwise, febrile episodes after chemotherapy
against solid tumours were rapidly controlled by the first and second line of
the anti-microbial strategy. Children treated for haematological malignancies
presented a lower response rate (P = 0.03).Conclusion. - In febrile and
neutropenic children treated with chemotherapy, the association
cefepime-amikacin appeared to be a safe empirical treatment. In a neutropenic
child, the immunodeficiency and possibly the clinical status should be the major
factors of the infectious prognosis more than the duration of aplasia.
PMID: 12818750 [PubMed - in process]
10: Rev Prat. 2003 May 1;53(9):950-7.
[In Process Citation]
[Article in French]
Richard JC.
Service de reanimation medicale Hopital Charles Nicolle 76031 Rouen.
jrichard@invivo.edu
Acute respiratory distress syndrome (ARDS) is a non cardiogenic pulmonary edema
that results from several pulmonary or extrapulmonary insults. ARDS respiratory
manifestations, in fact, represent the expression of a complex and diffuse
inflammatory process involving other organs. Mechanical ventilation is
considered to be a cornerstone of treatment. Alterations in respiratory mechanic
(decrease in compliance) mainly due to the reduction in non-atelectasis lung
volume, are responsible for the high airway pressure observed during mechanical
ventilation. Since mechanical ventilation, itself, could promote lung injury, a
ventilatory strategy combining both, low volumes to limit distension and
positive end expiratory pressure to recruit atelectasis may be beneficial. This
hypothesis has been recently confirmed in a study involving more than 800
patients, demonstrating that a simple ventilatory strategy based on recent
physiological knowledge may affect ARDS outcome.
PMID: 12816032 [PubMed - in process]
11: Eur Radiol. 2003 Jun 12 [Epub ahead of print].
Anterior axial ultrasound in monitoring infants with Pavlik harness.
Ferzli JE, Abuamara S, Eurin D, Dosseur PL, Dacher JN.
Department of Radiology, CHU Charles Nicolle, 1 rue de Germont, 76031, Rouen
Cedex, France.
Real-time ultrasonography has been used for diagnosis and screening of
developmental dysplasia of the hip for several years. If diagnostic criteria are
well established, the use of sonography in follow-up of treated infants remains
extremely variable. The aims of this study were (a) to describe the normal
sonographic anatomy of the infant abducted hip on an anterior axial view, and
(b) to define the role of this approach in the follow-up of developmental
dysplasia treated by Pavlik harness. Thirty-eight patients with Pavlik harness
had anterior axial sonograms in addition to their usual clinical and sonographic
follow-up. Normal anatomy was inferred from the examination of 25 clinically
proven normal hips in the same population. The best criterion of a normal
positioning of the femoral head appears to be the alignment of the pubic bone
and the femoral metaphysis. Pavlik harness was the only treatment in 32
patients. It was directly efficient in 22, after readjustment in 10 patients.
Reduction was shown by anterior sonography in all of them. In 6 children,
sonography showed no reduction and subsequent treatment by closed or open
reduction was carried out. Anterior axial sonogram can show reduction of a
dislocated hip in children with Pavlik harness, but it does not evaluate its
stability. It helps optimize the settings of the harness, and may predict a poor
outcome, but it does not identify the cause of non-reducibility.
PMID: 12802617 [PubMed - as supplied by publisher]
12: J Interv Cardiol. 2003 Jun;16(3):217-21.
A randomized comparison of a percutaneous suture device versus manual
compression for femoral artery hemostasis after PTCA.
Tron C, Koning R, Eltchaninoff H, Douillet R, Chassaing S, Sanchez-Giron C,
Cribier A.
Service de Cardiologie, Centre Hospitalo-Universitaire, Hopital Charles-Nicolle,
1 rue de Germont, 76000 Rouen, France. Christophe.Tron@chu-rouen.fr
BACKGROUND: The prolonged bed rest following femoral sheath removal after PTCA
is a source of discomfort for the patient. We designed a randomized study to
evaluate the efficacy and safety of an arterial suture device developed to
percutaneously close the vascular access site after PTCA, allowing immediate
sheath removal and early ambulation, compared to manual compression. METHODS:
After successful PTCA, patients were randomized to manual compression or
immediate femoral percutaneous closure. Exclusion criteria were arteritis, age >
80 years and > 3 previous femoral punctures on the same side. The two-needle
device was used for the 6F sheath removal and the four-needle device for the 8F
sheath. Ambulation was allowed 4 hours after the arterial suture. RESULTS: One
hundred and sixty-seven patients (59 +/- 10 years, 81% males) were randomized to
suture device (n = 91) or to manual compression (n = 76). The two groups were
similar in terms of age, sex, size of sheath, number of patients with stent
implantation (62 vs 61%), procedural anticoagulation. Procedural duration was 8
+/- 6 minutes with percutaneous suture versus 25 +/- 11 minutes with manual
compression (P < 0.0001). Procedural success with percutaneous suture was 93%
whereas six technical failures were treated with prolonged manual compression.
Nonsurgical hematoma occurred in five patients (5%) with the suture device and
in two (3%) with manual compression with no need for blood transfusion (P = NS).
Uneventful blood oozing occurred in 11 patients (12%) with percutaneous suture
and in only 2 (3%) with manual compression (P < 0.06). The tolerance of the
hemostasis procedure and the length of post-procedure hospital stay (40 +/- 32
hours) were similar in the two groups. CONCLUSION: Percutaneous suture of the
femoral artery, allows immediate closure of femoral puncture sites after PTCA,
without increasing the incidence of vascular complications. The use of this
device should allow earlier discharge and subsequent cost savings.
PMID: 12800399 [PubMed - in process]
13: Ultrasound Obstet Gynecol. 1992 Jan 1;2(1):51-4.
In utero early suspicion of superfetation by ultrasound examination: a case
report.
Soudre G, Guettier X, Marpeau L, Larue L, Jault T, Barrat J.
Department of Obstetrics and Gynecology, Hopital Saint-Antoine, Paris, France.
We report the case of a dichorionic and diamniotic pregnancy with the unique
feature of an early ultrasound diagnosis of a 4-week size difference, which
persisted throughout pregnancy. At birth, the twins had a 1-month difference in
physical and neurological maturity. We believe that only the phenomenon of a
superfetation can explain this difference. We report the cases found in the
literature. Copyright 1992 International Society of Ultrasound in Obstetrics and
Gynecology
PMID: 12797008 [PubMed]
14: J Pediatr Hematol Oncol. 2003 Jun;25(6):441-7.
Economic evaluation of recombinant human granulocyte colony-stimulating factor
in very high-risk childhood acute lymphoblastic leukemia.
Delorme J, Badin S, Le Corroller AG, Auvrignon AA, Auclerc MF, Gandemer V,
Bordigoni P, Lamagnere JP, Demeocq F, Perel Y, Berthou C, Bauduer F, Pautard B,
Vannier JP, Braguer D, Leblanc T, Leverger G, Baruchel A, Michel G.
PURPOSEIn a previous randomized study, the authors reported that granulocyte
colony-stimulating factor (G-CSF) increased the chemotherapy dose-intensity
delivered during the consolidation therapy of high-risk childhood acute
lymphoblastic leukemia (ALL). The aim of the current study was to perform an
economic evaluation in the same cohort.METHODSIn this open-label multicenter
randomized trial, prophylactic G-CSF was administered after consolidation
therapy courses. Economic data were retrospectively quantified for each patient:
hospital stays, drugs, and blood products.RESULTSSixty-seven children were
enrolled in the very high-risk branch of the FRALLE 93 protocol. Chemotherapy
dose-intensity was significantly increased (105 +/- 5% in the G-CSF group vs. 91
+/- 4% in the non-G-CSF group, P < 0.001). The mean total costs per child were
not statistically different: $32,309 in the G-CSF group versus $31,569 in the
non-G-CSF group. Further analysis per child and per course (R3 or COPADM)
demonstrated that the mean cost of hospitalization and the mean cost of
intravenous antibiotics were significantly decreased in the G-CSF group after R3
courses ($3,857 vs. $4,993.80, P < 0.001; $171.40 vs. $306.20, P = 0.029,
respectively), but the cost of platelet transfusion was significantly increased
(P = 0.03). Conversely, post-COPADM costs were similar. Finally, mean costs per
course in the two randomized groups were not significantly different: $5,848.80
versus $6,181 and $7,388.10 versus $6,475.70 for R3 and COPADM, respectively.
The 3-year probability of event-free survival between the two groups was not
different.CONCLUSIONSG-CSF can increase chemotherapy dose-intensity in very
high-risk ALL without raising costs, but event-free survival was not improved.
The cost benefit of prophylactic treatment by G-CSF relies on the
chemotherapeutic regimen given prior to G-CSF administration.
PMID: 12794521 [PubMed - in process]
15: J Acquir Immune Defic Syndr. 2003 May 1;33(1):1-7.
Plasma RNA quantification and HIV-1 divergent strains.
Plantier JC, Gueudin M, Damond F, Braun J, Mauclere P, Simon F.
Laboratoire de Virologie, GRAM IFR 23 CHU Charles Nicolle, Rouen, France.
Jean_Christophe.Plantier@chu-rouen.fr
The diversity of HIV complicates viral load measurement for patient management
and treatment monitoring. Numerous studies have shown that non-B group M
variants can be underestimated and that group O strains are not detected by
commercial tests. More recent versions of the kits used for previous studies
have improved the quantification of non-B variants but are still unable to
detect or correctly quantify group O strains. In this study, the authors
evaluated the new Abbott LCx HIV RNA Quantitative viral load kit with a large
collection of samples from Europe and central Africa. One hundred thirty-three
group M samples, including 69 from patients infected with non-B variants, and 70
group O samples were tested. The LCx system was compared with the Cobas Amplicor
HIV-1 Monitor v1.5 test and with a quantitative real-time polymerase chain
reaction method based on LightCycler technology. The LCx and Cobas tests had
similar quantification ranges for group M samples and a high degree of linearity
(r2 = 0.9582). The LCx method quantified group O variants (31 of the 48 patients
were quantifiable) and gave values within the range of those obtained with the
LightCycler assay. The two assays were sensitive but showed only moderate
linearity (r2 = 0.6195), probably because of higher diversity of group O strains
and the use of primers and probes in different regions. In conclusion, the
authors showed that the LCx kit allowed quantification of the large group M
diversity and group O variants.
PMID: 12792348 [PubMed - indexed for MEDLINE]
16: Science. 2003 Jun 6;300(5625):1532-4.
Regulators of cerebellar granule cell development act through specific signaling
pathways.
Vaudry D, Falluel-Morel A, Leuillet S, Vaudry H, Gonzalez BJ.
European Institute for Peptide Research (IFRMP 23), Laboratoryof Cellular and
Molecular Neuroendocrinology, INSERM U413, University of Rouen, 76821
Mont-Saint-Aignan, France. david.vaudry@univ-rouen.fr
The proper development of the central nervous system depends upon a finely tuned
balance between cell proliferation and programmed cell death (PCD). Although PCD
was initially believed to depend solely on the inability of certain neurons to
obtain access to a limited supply of trophic factors, it has become apparent
that the local production of death signals is also critical. In this Viewpoint,
we discuss several pathways implicated in the survival of cerebellar granule
cells- both pathways that protect from apoptosis and pathways that promote
apoptosis-and describe how these disparate pathways converge on the final common
mediators of PCD. Information on other important pathways implicated in granule
cell survival may be found in the Connections Maps.
PMID: 12791981 [PubMed - indexed for MEDLINE]
17: Eur J Pharm Sci. 2003 Jun;19(2-3):129-32.
Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution
conditions on in vitro drug release.
Marchais H, Cayzeele G, Legendre JY, Skiba M, Arnaud P.
Laboratoire de Pharmacie Galenique et Biopharmacie, ADEN-UPRES EA 3234, UFR de
Medecine-Pharmacie, 22 Boulevard Gambetta, 76183 Cedex, Rouen, France
The aim of this study was to determine if the use of both enzyme and surfactant
in the dissolution medium changes the in vitro drug release from cross-linked
hard gelatin capsules containing a water-insoluble drug. Hard gelatin capsules
were cross-linked by a controlled exposure to formaldehyde resulting in
different stressed capsules and carbamazepine (CBZ) was chosen as a drug model.
In vitro dissolution studies were conducted using simulated gastric fluid (SGF)
and simulated intestinal fluid (SIF) with enzymes. Sodium lauryl sulfate (SLS)
was added in the dissolution medium at a concentration of 2% m/v both in SGF and
SIF with pepsin and pancreatin, respectively. The percentage of CBZ dissolved
was reduced by increasing the degree of gelatin cross-linking. For unstressed
hard gelatin capsules, 36% of the CBZ was released after 1 h, lowering to 5% for
highly stressed hard gelatin capsules in the SGF. A similar effect was observed
with SIF. In the case of moderately stressed hard gelatin capsules, addition of
enzyme in the dissolution medium enhanced the percentage of CBZ dissolved. The
dissolution level increased from 12% to 39% in SGF with pepsin for hard gelatin
capsules cross-linked with 1500 ppm formaldehyde. On the contrary, the use of
enzyme in the dissolution medium did not increase the dissolution of CBZ from
highly stressed hard gelatin capsules. Surprisingly, the addition of SLS in the
medium did not allow the release of the CBZ both in SGF and in SIF. The results
of this study demonstrate that the use of enzyme in the dissolution medium is
justified for moderately cross-linked hard gelatin capsules. However, the action
of a surfactant added in the medium containing enzyme remains unclear.
PMID: 12791415 [PubMed - in process]
18: J Clin Endocrinol Metab. 2003 Jun;88(6):2579-85.
Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas
as a potential marker for discriminating benign versus malignant tumors.
Yon L, Guillemot J, Montero-Hadjadje M, Grumolato L, Leprince J, Lefebvre H,
Contesse V, Plouin PF, Vaudry H, Anouar Y.
European Institute for Peptide Research (IFRMP 23), Laboratory of Cellular and
Molecular Neuroendocrinology, INSERM, Unite 413, Unite Associee CNRS, University
of Rouen, Mont-Saint-Aignan, France.
EM66 is a novel secretogranin II-derived peptide present in chromaffin cells of
the human adrenal gland. The aim of the present study was to investigate the
possible occurrence of EM66 in benign and malignant pheochromocytomas.
Immunohistochemical labeling using specific antibodies revealed intense staining
in both benign and malignant tumors. Coincubation of pheochromocytoma slices
with EM66 and tyrosine hydroxylase antibodies showed that the immunostaining was
restricted to chromaffin cells. RIA experiments indicated that serial dilutions
of extracts of benign and malignant tumors generated displacement curves that
were parallel to those produced by recombinant EM66. RIA quantification revealed
concentrations of EM66 immunoreactivity ranging from 3.2-210 ng/mg protein
(median = 25.6 ng/mg protein) in benign pheochromocytomas, and from 2.9-6.3
ng/mg protein (median = 3.8 ng/mg protein) in malignant tumors. The EM66-like
immunoreactivity contained in the pheochromocytoma extracts was characterized by
HPLC analysis combined with RIA detection. All of the benign and malignant
tumors examined exhibited a single immunoreactive peak coeluting with
recombinant EM66. These data indicate that the secretogranin II-derived peptide
EM66 is generated in human tumoral chromaffin tissue. The significant difference
in EM66 concentrations observed between benign and malignant pheochromocytomas
suggests that measurement of EM66 levels may help identifying patients with
higher risk of progression of such tumors.
PMID: 12788858 [PubMed - in process]
19: Brain Res. 2003 Jul 4;977(1):38-45.
Transgenic mice expressing the betaAPP(695)SWE mutation: effects on exploratory
activity, anxiety, and motor coordination.
Lalonde R, Lewis TL, Strazielle C, Kim H, Fukuchi K.
Universite de Rouen, Faculte de Medecine et de Pharmacie, 22 bld Gambetta,
INSERM EMI 9906, IFRMP 23, Batiment de Recherche, Salle 1D18, 76183 Cedex,
Rouen, France
The functional consequences of the betaAPP transgene with the Swedish mutation
in mice were assessed in tests of exploratory activity and motor coordination.
The betaAPP(695)SWE (Tg2576) transgenic mice are characterized by Abeta plaque
formation in the neocortex and hippocampus. By comparison to non-transgenic mice
controlled for age and gender, 17-month-old betaAPP(695)SWE transgenic mice
displayed impaired spontaneous alternation, increased activity levels in the
peripheral part of the open-field, and reduced anxiety in the elevated
plus-maze. These results are similar to the loss of inhibitory control observed
in some patients with Alzheimer's disease. These measures may be added to
cognitive dysfunctions as testing ground for Abeta vaccination and other
attempts at experimental therapies.
PMID: 12788511 [PubMed - in process]
20: Cell Mol Life Sci. 2003 Apr;60(4):810-9.
Fenofibrate inhibits angiogenesis in vitro and in vivo.
Varet J, Vincent L, Mirshahi P, Pille JV, Legrand E, Opolon P, Mishal Z, Soria
J, Li H, Soria C.
Laboratoire DIFEMA, Faculte de Medecine et Pharmacie, 22 Boulevard Gambetta,
76183 Rouen, France.
Fenofibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha
activator, used as a normolipidemic agent, is thought to offer additional
beneficial effects in atherosclerosis. Since angiogenesis is involved in plaque
progression, hemorrhage, and instability, the main causes of ischemic events,
this study was designed to evaluate the action of fenofibrate on angiogenesis.
Our results show that fenofibrate (i) inhibits endothelial cell proliferation
induced by angiogenic factors, followed at high concentrations by an increase in
apoptosis, (ii) inhibits endothelial cell migration in a healing wound model,
(iii) inhibits capillary tube formation in vitro, and (iv) inhibits angiogenesis
in vivo. Concerning the mechanism of action, the inhibition of endothelial cell
migration by fenofibrate can be explained by a disorganization of the actin
cytoskeleton. At the molecular level, fenofibrate markedly decreased basic
fibroblast growth factor-induced Akt activation and cyclooxygenase 2 gene
expression. This inhibition of angiogenesis could participate in the beneficial
effect of fenofibrate in atherosclerosis.
PMID: 12785728 [PubMed - indexed for MEDLINE]
21: Br J Haematol. 2003 Jun;121(5):786-792.
Biological and clinical features of low-molecular-weight heparin-induced
thrombocytopenia.
Gruel Y, Pouplard C, Nguyen P, Borg JY, Derlon A, Juhan-Vague I, Regnault V,
Samama M; The French Heparin-Induced Thrombocytopenia Study Group.
Tours Laboratoire d'hematologie hemostase, Reims Laboratoire d'hematologie
hemostase, Rouen Laboratoire d'hematologie hemostase, Caen Laboratoire
d'hematologie hemostase, Marseille Laboratoire d'hematologie hemostase,
Vandoeuvre les Nancy Laboratoire d'hematologie hemostase, and Paris Laboratoire
d'hematologie hemostase, France.
Heparin-induced thrombocytopenia (HIT) is a common adverse effect of
unfractionated heparin (UFH) therapy. In contrast, only a few patients have been
reported with HIT following low-molecular-weight heparin (LMWH) therapy
(LMW-HIT). To define the clinical and biological characteristics of LMW-HIT, 180
patients treated for suspected HIT at 15 French centres were investigated.
Clinical history was recorded and HIT was confirmed in 59 patients with positive
serotonin release assay results: 57 of them had high levels of antibodies (Abs)
to heparin-platelet factor 4 complexes (H/PF4) and two had Abs to interleukin 8.
Eleven patients were treated exclusively with LMWH (LMW-HIT) and 48 with UFH
either alone (UF-HIT, n = 34) or combined with LMWH (UF/LMW-HIT, n = 14). The
LMW-HIT and UF-HIT groups were similar with respect to sex, age, platelet count
before heparin therapy, frequency of bleeding and occurrence of disseminated
intravascular coagulation. The interval to onset of HIT was longer in LMW-HIT
patients compared with UF-HIT patients (P = 0.03). Severe thrombocytopenia
(platelets < 15 x 109/l) was more frequent in the LMW-HIT group (P = 0.04).
Thrombosis occurred in three of 11 LMW-HIT patients, i.e. as frequently as in
UF-HIT patients. LMW-HIT is potentially severe and may be observed after longer
heparin treatment compared with UF-HIT. It is highly recommended, therefore,
that platelet counts be monitored carefully whenever LMWH is administered.
PMID: 12780795 [PubMed - as supplied by publisher]
22: Colorectal Dis. 2002 Sep;4(5):321-325.
Treatment of enterocele by abdominal colporectosacropexy - efficacy on pelvic
pressure.
Jean F, Tanneau Y, Le Blanc-Louvry I, Leroi AM, Denis P, Michot F.
Digestive Tract Research Group, Rouen University Hospital, Rouen, France.
OBJECTIVE: Enterocele induces pelvic pressure, obstructed defaecation, lower
abdominal pain and/or false urge to defaecate in patients. The aim of this study
was to evaluate the efficacy of abdominal colporectosacropexy in these symptoms,
especially on pelvic pressure. METHODS: Sixty-two consecutive women with
enterocele were included. All patients were symptomatic because they had: pelvic
pressure (n = 62), obstructed defaecation (n = 40), lower abdominal pain (n = 8)
or faecal incontinence (n = 16). Defaecography confirmed enterocele in all
patients. The surgical procedure was performed by the same surgeon and was an
abdominal colporectosacropexy with a nonabsorbable Prolene(R) mesh. After
surgery, clinical evaluation (62/62 patients) and a telephone questionnaire
(56/62 patients) were performed, respectively, 3 months and 27 +/- 13 months
after surgery. RESULTS: Defaecography showed rectal abnormalities associated
with enterocele in 59/62 patients (rectocele, rectal prolapse). No recurrence of
enterocele was observed 3 months after surgery, but 1 patient demonstrated
recurrence 10 months after surgery. Pelvic pressure was less frequent after
abdominal colporectosacropexy, than before surgery (P < 0.01): pelvic pressure
totally disappeared in 41/56 patients, and partially in 10/56 patients. The
number of patients with obstructed defaecation, lower abdominal pain, or faecal
incontinence was not different before and 27 months after surgery. The number of
patients with urinary incontinence was also not different before and after
surgery (30 and 27 patients). CONCLUSIONS: This study of a large number of
patients with enterocele shows that abdominal colporectosacropexy improves
pelvic pressure in most patients and does not modify urinary status.
PMID: 12780575 [PubMed - as supplied by publisher]
